Back to Search
WILLIAM GRADISHAR, MD
MD
Medical Oncology Physician
NPI: 1437187929IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
036067208(IL)
Education
UNIVERSITY OF ILLINOIS COLLEGE OF MED (CHI/PEOR/ROCK/CHM-URB)
Class of 1982
Research & Publications (20)
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
PMID 19470941·J Clin Oncol·2009
3-trial
Case records of the Massachusetts General Hospital. Case 30-2008. A 47-year-old woman with a mass in the breast and a solitary lesion in the spine.
PMID 18815400·N Engl J Med·2008
5-case
Albumin-bound paclitaxel: a next-generation taxane.
PMID 16722814·Expert Opin Pharmacother·2006
4-observational
Landmark trials in endocrine adjuvant therapy for breast carcinoma.
PMID 16435388·Cancer·2006
6-review
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
PMID 16172456·J Clin Oncol·2005
3-trial
Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
PMID 16088229·Oncology·2005
6-review
Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
PMID 16001952·Expert Rev Anticancer Ther·2005
6-review
Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer.
PMID 15905305·Ann Oncol·2005
3-trial
The future of breast cancer: the role of prognostic factors.
PMID 15770535·Breast Cancer Res Treat·2005
6-review
Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.
PMID 15197193·J Clin Oncol·2004
3-trial
Adjuvant systemic therapy of early stage breast cancer.
PMID 12594940·Curr Treat Options Oncol·2003
6-review
Progress in systemic adjuvant therapy of early-stage breast cancer.
PMID 12955580·Int J Clin Oncol·2003
6-review
Advances in endocrine therapy for the treatment and prevention of breast cancer.
PMID 15338746·Cancer Chemother Biol Response Modif·2003
6-review
A rationale for the reinitiation of adjuvant tamoxifen therapy in women receiving fewer than 5 years of therapy.
PMID 11899359·Clin Breast Cancer·2002
4-observational
The evolving role of endocrine therapy for the treatment and prevention of breast cancer.
PMID 12703207·Cancer Chemother Biol Response Modif·2002
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 675 N SAINT CLAIR ST, GALTER 21-100
CHICAGO, IL 60611 - Phone
- (312) 695-0990
Quick Facts
- NPI
- 1437187929
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 44
- Publications
- 20
Are you this provider?
Claim Your Profile